Obesity pill Orforglipron data expected in April 2025: Eli Lilly exec

London: Eli Lilly executive said that data from the late-stage trial of their experimental obesity pill, orforglipron, is anticipated to be released in April 2025.

The pill is part of a class of drugs known as incretins designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow the rate at which the stomach empties of food and decrease appetite.

Drugs from the class are also being tested to treat Alzheimer’s.
According to a Reuters report, Patrik Jonsson, President of Lilly Diabetes and Obesity, speaking at a Goldman Sachs healthcare conference, said his company is not convinced that the drug will help with the disease itself, but might help with underlying conditions like obesity and stroke that lead to cognitive decline.

Meidcal Dialogues team had earlier reported that Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, had collaborated with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform.

Read also: Aktis Oncology partners Eli Lilly to discover, develop anticancer radiopharmaceuticals

Facebook Comments